<DOC>
	<DOCNO>NCT02533544</DOCNO>
	<brief_summary>This open-label , single arm cohort study see efficacy safety tenofovir disoproxil fumarate ( TDF ) naïve chronic hepatitis B , retrospectively prospectively .</brief_summary>
	<brief_title>Treatment Efficacy Safety Tenofovir Disoproxil Fumarate ( TDF ) naïve Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Must ability understand sign write informed consent form , must obtain prior initiation study procedure . 2 . Adult male nonpregnant , nonlactating female subject , 19 year age old , base date screen visit . A negative serum pregnancy test Screening require female subject childbearing potential ( unless surgically sterile great 2 year postmenopausal ) . 3 . Documented evidence chronic HBV infection ( e.g . HBsAg positive 6 month ) 4 . Chronic hepatitis B following : HBeAgpositive HBeAb negative Screening Screening HBV DNA ≥ 1x 105 copies/mL Screening serum ALT level ≥ ×ULN ( 80 IU/L ) ≤ 10 ×ULN ( center laboratory range ) OR HBeAgnegative HBeAb positive Screening Screening HBV DNA ≥ 1x 104 copies/mL Screening serum ALT level ≥ ×ULN ( 80 IU/L ) ≤ 10 ×ULN ( center laboratory range ) OR Cirrhosis Screening Screening HBV DNA ≥ 1x 104 copies/mL HBeAg negative Screening HBV DNA ≥ 1x 105 copies/mL HBeAg positive Screening serum ALT level ≥ ×ULN ≤ 10 ×ULN ( center laboratory range ) 5 . A patient treating TDF treatmentnaïve Hepatitis B . Treatment naïve subject define history antiviral therapy &lt; 12 week oral antiviral treatment nucleoside nucleotide analogue , include lamivudine adefovir , clevudine , telbivudine , entecavir 6 . Decompensated liver cirrhosis define base ChildTurcottePugh ( CTP ) score ≥ 7 ( Child B C ) presence least one episode ascites , jaundice , hepatic encephalopathy variceal bleed 7 . Any previous treatment interferon ( pegylated nonpegylated ) must end least 6 month prior baseline visit 8 . Must willing able comply study requirement . Subjects meet follow exclusion criterion enrol study . 1 . Pregnant woman , woman breastfeed believe may wish become pregnant course study . 2 . Coinfection HCV , HIV 3 . Evidence hepatocellular carcinoma ( e.g . αfetoprotein &gt; 50 ng/mL evidence recent ultrasound standard care measure ) 4 . Malignancy within 5 year prior screen , exception specific cancer cure surgical resection ( basal cell skin cancer , etc ) . Subjects evaluation possible malignancy eligible 5 . Current alcohol substance abuse judge investigator potentially interfere subject compliance 6 . Currently receive therapy cytotoxic agent , nephrotoxic agent , agent capable modify renal excretion 7 . Any clinical condition prior therapy , opinion Investigator , would make subject unsuitable study unable comply dose requirement .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>tenofovir disoproxil fumarate</keyword>
</DOC>